secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2023-12-06T23:59:59+00:00
Accession:  0001104659-23-123807
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 1.02, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel Therapeutics amends credit agreement, terminates RIFA, lowers warrant exercise price to $3.6452
--------------------------------------------------------------------------------

- Entered Second Amendment to Credit Agreement with Oaktree; converts $30M RIFA financing into Tranche A-2 Term Loan.
- Increased OnkosXcel investment cap to $30.865M; pays 0.25% exit fee on loans repaid.
- Reduces exercise price of existing warrants from $20.04 to $3.6452; issues new warrants for 69,630 shares at same price.
- Terminates Revenue Interest Financing Agreement (RIFA); all future funding commitments cancelled.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465923123807/0001104659-23-123807-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465923123807/tm2332261d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-123807

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer